Cargando…
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
PURPOSE: Two chimeric antigen receptor T-cell (CAR-T) therapies have been approved in the United States (USA) in 2017 and Europe (EU) in 2018: axicabtagene ciloleucel and tisagenlecleucel. They contain the patient’s own T cells, which are extracted, genetically modified, and reinfused. Alongside the...
Autores principales: | Bonaldo, Giulia, Montanaro, Nicola, AlbertoVaccheri, Motola, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275491/ https://www.ncbi.nlm.nih.gov/pubmed/33608749 http://dx.doi.org/10.1007/s00228-021-03106-z |
Ejemplares similares
-
The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012) -
Systematic review of safety in paediatric drug trials published in 2007
por: Nor Aripin, Khairun Nain Bin, et al.
Publicado: (2011) -
Safety of azithromycin in pediatrics: a systematic review and meta-analysis
por: Zeng, Linan, et al.
Publicado: (2020) -
Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand
Publicado: (2016) -
The nocebo effect challenges the non-medical infliximab switch in practice
por: Boone, N. W., et al.
Publicado: (2018)